🇺🇸 AMGN — Amgen Inc.

Healthcare Compra
← Volver

Precio actual

437,23 USD

Máx. histórico

447,03

10 días

Split 2:1 del 22/11/1999

Caída desde máximo

-2,19%

Rango 52 semanas

269,77 – 447,03

Variación hoy

-1,55%

Cierre anterior

444,12

Rango de hoy

435,01 – 441,66

Volumen hoy

1.656.089

Información
Nombre completo
Amgen Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Healthcare
Industria
Drug Manufacturers - General
Empleados
31.500
PER
27,17 (puede no estar actualizado)
Dividend yield
2,31% (puede no estar actualizado)
Precio objetivo analistas
389,69 USD (puede no estar actualizado)
Primera cotización
17/06/1983
Precio actualizado
hace 3 días
Sobre la empresa

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Dividendos repartidos Total últimos 12 meses: 9,9400 USD · Yield: 2,27%
Fecha de pago Importe por participación
21/08/2026 2,5200 USD
15/05/2026 2,5200 USD
13/02/2026 2,5200 USD
21/11/2025 2,3800 USD
22/08/2025 2,3800 USD
16/05/2025 2,3800 USD
14/02/2025 2,3800 USD
18/11/2024 2,2500 USD
16/08/2024 2,2500 USD
16/05/2024 2,2500 USD
15/02/2024 2,2500 USD
16/11/2023 2,1300 USD
17/08/2023 2,1300 USD
17/05/2023 2,1300 USD
14/02/2023 2,1300 USD
Splits Registrados en el histórico de precios
Fecha Ratio
22/11/1999 2:1
01/03/1999 2:1
16/08/1995 2:1
11/09/1991 3:1
13/08/1990 2:1
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
24/02/2009 56,83 56,99 56,22 56,80 +1,19% 1,35% 9.773.800
23/02/2009 56,86 57,12 56,00 56,13 -0,99% 1,97% 8.372.200
20/02/2009 56,82 57,55 55,99 56,69 -0,68% 2,75% 10.282.600
19/02/2009 57,73 57,97 56,98 57,08 -0,54% 1,71% 6.497.800
18/02/2009 56,39 57,75 56,30 57,39 +1,74% 2,57% 8.625.900
17/02/2009 56,90 57,36 56,25 56,41 -2,57% 1,95% 8.469.900
13/02/2009 58,26 58,77 57,80 57,90 -0,87% 1,66% 5.358.800
12/02/2009 57,51 58,46 57,10 58,41 +0,69% 2,36% 8.704.400
11/02/2009 57,44 58,20 57,15 58,01 +1,05% 1,83% 7.494.800
10/02/2009 58,24 58,84 57,25 57,41 -2,26% 2,73% 9.289.400
09/02/2009 58,00 58,89 57,85 58,74 +1,22% 1,79% 7.402.100
06/02/2009 57,10 58,13 56,82 58,03 +1,61% 2,29% 7.888.600
05/02/2009 56,08 57,20 55,49 57,11 +0,60% 3,05% 6.880.400
04/02/2009 56,79 57,85 56,17 56,77 +0,19% 2,96% 7.420.500
03/02/2009 55,77 56,91 55,45 56,66 +2,35% 2,62% 7.668.400
02/02/2009 54,43 55,71 54,30 55,36 +0,93% 2,59% 7.060.400
30/01/2009 54,59 55,81 54,51 54,85 +0,05% 2,38% 8.037.600
29/01/2009 54,15 55,27 54,15 54,82 +0,13% 2,07% 7.668.400
28/01/2009 53,67 55,23 53,24 54,75 +3,13% 3,71% 9.199.100
27/01/2009 53,40 53,77 52,45 53,09 -2,43% 2,47% 12.635.600
26/01/2009 53,30 54,72 52,55 54,41 +2,29% 4,07% 10.053.400
23/01/2009 54,48 54,98 53,00 53,19 -3,69% 3,63% 9.870.400
22/01/2009 54,84 55,57 54,20 55,23 -0,54% 2,50% 6.305.300
21/01/2009 55,49 55,70 54,05 55,53 +0,96% 2,97% 9.451.300
20/01/2009 56,99 57,79 54,92 55,00 -4,38% 5,04% 8.660.200
16/01/2009 57,62 57,76 56,72 57,52 +0,63% 1,80% 7.020.300
15/01/2009 55,76 57,29 55,22 57,16 +1,93% 3,71% 8.330.400
14/01/2009 56,75 57,26 55,75 56,08 -2,82% 2,66% 6.634.600
13/01/2009 57,16 58,03 57,05 57,71 +1,14% 1,71% 7.466.600
12/01/2009 57,58 57,72 56,34 57,06 -1,25% 2,40% 7.698.300